Table 3.
Type-specific persistence, regression and progression of incident HPV 6, 11, 16, 18 infections
| Proportion Persisting Without CIN Due to Type (95% CI) | Proportion for Which Type Regressed (95% CI) | Proportion Progressed to CIN 1 Due to Type (95% CI) | Proportion Progressed to CIN 2 Due to Type (95% CI) | Proportion Progressed to CIN 3 Due To Type (95% CI) | |
| HPV 6 (n = 103) | |||||
| 12 Months | 26.0 (17.5, 35.0) | 62.3 (52.9, 71.8) | 9.6 (4.0, 15.5) | 2.1 (0.0, 5.5) | 0.0 (-) |
| 24 Months | 0.0 (-) | 84.0 (75.5, 91.3) | 13.9 (6.7, 21.1) | 2.1 (0.0, 5.5) | 0.0 (-) |
| 36 Months | 0.0 (-) | 84.0 (75.5, 91.3) | 13.9 (6.7, 21.1) | 2.1 (0.0, 5.5) | 0.0 (-) |
| HPV 11 (n = 13) | |||||
| 12 Months | 14.6 (0.0, 42.9) | 85.4 (57.1, 100.0) | 0.0 (-) | 0.0 (-) | 0.0 (-) |
| 24 Months | 0.0 (-) | 100.0 (-) | 0.0 (-) | 0.0 (-) | 0.0 (-) |
| 36 Months | 0.0 (-) | 100.0 (-) | 0.0 (-) | 0.0 (-) | 0.0 (-) |
| HPV 16 (n = 142) | |||||
| 12 Months | 47.2 (37.9, 56.6) | 35.4 (27.3, 44.5) | 10.5 (5.7, 16.5) | 4.5 (1.0, 8.6) | 2.4 (0.0, 5.5) |
| 24 Months | 15.8 (8.6, 24.8) | 53.0 (43.5, 63.2) | 18.3 (11.5, 26.0) | 9.1 (3.8, 14.8) | 3.8 (0.8, 8.2) |
| 36 Months | 0.0 (0.0, 7.1) | 62.8 (50.0, 73.1) | 20.7 (12.1, 29.6) | 9.1 (3.8, 14.8) | 7.4 (1.9, 14.0) |
| HPV 18 (n = 62) | |||||
| 12 Months | 52.9 (38.9, 67.1) | 34.8 (22.3, 48.2) | 6.8 (1.6, 13.7) | 5.5 (0.0, 12.2) | 0.0 (-) |
| 24 Months | 16.3 (5.3, 28.7) | 66.0 (51.4, 79.0) | 9.5 (1.9, 18.5) | 5.5 (0.0, 12.2) | 2.7 (0.0, 9.6) |
| 36 Months | 8.2 (0.0, 23.1) | 74.1 (55.9, 89.5) | 9.5 (1.9, 18.5) | 5.5 (0.0, 12.2) | 2.7 (0.0, 9.6) |
CIN = cervical intraepithelial neoplasia; HPV = human papillomavirus; CI = confidence interval